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Cyclodextrins (CDs) are cyclic oligosaccharides composed of D-glucopyranoside units linked by 
glycosidic bonds. Their main property is the ability to modify the physicochemical and biological 
characteristics of low-soluble drugs through the formation of drug:CD inclusion complexes. Inclusion 
complexation requires that host molecules fit completely or partially within the CD cavity. This adjustment 
is directly related to the physicochemical properties of the guest and host molecules, easy accommodation 
of guest molecules within the CD cavity, stoichiometry, therapeutic dose, and toxicity. However, dosage 
forms may achieve a high volume, depending on the amount of CD required. Thus, it is necessary 
to increase solubilization efficiency in order to use smaller amounts of CD. This can be achieved by 
adding small amounts of water-soluble polymers to the system. This review addresses aspects related 
to drug complexation with CDs using water-soluble polymers to optimize the amount of CD used in the 
formulation in order to increase drug solubility and reduce dosage form volume.  
Uniterms: Cyclodextrins. Ternary complexes. Drugs/complexation. Water-soluble polymers/use. Drugs/
solubility. Inclusion complexe. 
Ciclodextrinas (CDs) são oligossacarídeos cíclicos, compostos por unidades D-glicopiranosídicas 
ligadas entre si por meio de ligações glicosídicas e sua principal propriedade está na capacidade de 
alterar as características físico-químicas e biológicas de fármacos com baixa solubilidade por meio da 
formação de complexos de inclusão fármaco:CD. Para a formação dos complexos de inclusão a molécula 
hospedeira necessita ajustar-se total ou parcialmente no interior da cavidade da CD, onde este ajuste 
está diretamente ligado a propriedades físico-químicas da molécula hóspede e hospedeira, facilidade 
de alojamento da molécula hóspede no interior da cavidade da CD, estequiometria, dose terapêutica 
e toxicidade. No entanto, as formas farmacêuticas podem atingir um elevado volume, em função da 
quantidade de CD requerida, sendo necessário aumentar sua eficiência de solubilização para que seja 
possível utilizar menores quantidades das mesmas. Isso pode ser obtido com a inclusão de pequenas 
quantidades de polímeros hidrossolúveis ao sistema. Nessa revisão, são abordados aspectos relacionados 
à complexação de fármacos com ciclodextrinas empregando-se polímeros hidrossolúveis para otimização 
da quantidade de CD utilizada na formulação, com a finalidade de aumentar a solubilidade do fármaco 
e reduzir o volume das preparações. 
Unitermos: SCiclodextrinas. Complexos ternários. Fármacos/complexação. Polímeros hidrossolúveis/
uso. Fármacos/solubilidade. Complexos de inclusão. 
INTRODUCTION
Among several factors, solubility in water is of 
paramount importance in the development of a sufficiently 
safe and effective dosage formulation, because prepara-
tion, absorption and even the biological activity of a drug 
are all dependent on its solubility. However, the amount 
of lipophilic molecules used in treatment is relatively high 
and tends to increase, considering that many different 
drugs have low solubility (Lipinski, 2000; Grant, Zhang, 
2011).
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Thus, use of cyclodextrins (CDs) is one of several 
technologies available to improve the solubility of poorly 
water-soluble drugs. The most remarkable property of CDs 
is their ability to modify the physicochemical character-
istics of molecules that are accommodated within their 
internal cavity to form the so-called inclusion complexes 
(Loftsson, Brewster, 1997; Tsai et al., 2010).
Typical characteristics of formulations containing 
inclusion complexes include a faster dissolution rate and 
shorter drug release time, as well as more efficient absorp-
tion. This translates into greater oral bioavailability of 
the drugs involved and an increase in biological activity, 
which may result in a reduction in drug dosage (Valle, 
2004; Garnero et al., 2010).
However, the use of CDs is limited in some cases, 
because guest molecules need to fit completely or partially 
within the CD cavity. This adjustment is directly related 
to the physicochemical properties of the guest and host 
molecules, easy accommodation of guest molecules within 
the CD cavity, stoichiometry, therapeutic dose, and CD 
toxicity (Loftsson, Brewster, 1997). 
An increase in formulation volume represents a criti-
cal stage in the applicability of CD inclusion complexes. 
We can consider that 1 g of a solid complex corresponds to 
100-250 mg of a drug (when the molecular weights of the 
drug and the CD are 200-400 g/mol and 1200-1500 g/mol, 
respectively). Therefore, the use of CDs in oral solid dosage 
forms is limited to drug doses less than 200 mg that have 
good complexation properties (Loftsson, Brewster, 1996).
A strategy often used to improve complexation 
between drugs and CDs is the addition of small amounts 
of water-soluble polymers to the system, which causes 
an increase in solubilization efficiency, while requiring 
smaller amounts of CD (Loftsson, Fridriksdóttir, 1998; 
Mura et al., 2001). These results can be attributed to the 
synergistic effect of polymer and CD solubilization on 
the formation of drug:CD:water-soluble polymer ternary 
complexes (Carrier et al., 2007).
Water-soluble polymers are able to interact with 
drugs, CD molecules, and even with drug:CD complexes 
(Loftsson et al., 1996). The mechanism involved in in-
creasing CD complexation efficiency in the presence of 
water-soluble polymers is not yet fully understood; how-
ever, it is believed that water-soluble polymers can reduce 
CD mobility and increase the complex solubility (Veiga 
et al., 2006). The addition of water-soluble polymers has 
been shown to increase drug bioavailability and cause an 
up to 80% reduction in the amount of CD required (Lofts-
son, Fridriksdóttir, 1998; Mura et al., 2001).
The purpose of this study is to outline the relevance 
of using CDs to improve the solubility of poorly water-
soluble drugs, with special emphasis on their structural 
characteristics, physicochemical properties, productive 
processes, toxicity, derivatives, and use in the pharmaceu-
tical industry. Despite the recognized benefits of ternary 
(drug:CD:water-soluble polymer) complexes, there have 
been no reviews on the subject in the scientific literature. 
This review addresses aspects related to drug complex-
ation with CDs using water-soluble polymers to increase 
drug solubility and reduce dosage form volume.
CYCLODEXTRINS (CDs)
CDs are cyclic oligosaccharides composed of D-
glucopyranoside units (glucose) linked by α-1.4 glycosidic 
bonds. They are obtained from biotechnological processes 
involving the enzymatic degradation of corn starch and of-
fer greater yield with 6, 7 and 8 units of glucose, known as 
α-CD, β-CD and γ-CD, respectively (Szejtli, 1998; Heise 
et al., 2010) (Figure 1).
CDs with less than 6 units of glucose do not exist for 
stoichiometric reasons and those with more than 8 units 
offer low yields and weak complexing properties, thus 
making them unsuitable for the pharmaceutical industry 
(Loftsson, Brewster, 1997; Jug et al., 2011).
According to Szejtli (2004), the history of CDs can 
be divided into three distinct periods (Figure 2), as follows: 
(a) discovery, from 1891 to 1930; (b) development, from 
1930 to 1970, and (c) industrial use, from 1970 onwards.
In the beginning of the industrial production of CDs 
FIGURE 1 - Chemical structure of α-, β- and γ-cyclodextrins, respectively. Adapted from Veiga et al., 2006.
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groups can be found at the broadest end, bonded to the 
C2 and C3 atoms of the glucose units, while the primary 
hydroxyl groups are located at the narrower opposite end, 
bonded to the C6 atoms of the glucose units (Bekers et al., 
1991; Loftsson et al., 2004; Veiga et al., 2006).
The molecular arrangement of CDs is a result of the 
free rotation of primary hydroxyl groups, which reduces 
the diameter of the cavity at its narrowest end, i.e., the end 
with the smallest molecular diameter. CH groups bonded 
to the H1, H2 and H4 hydrogen atoms can be found on 
the outside of the molecule, while the hydroxyls find their 
way outside the truncated cone, thus becoming the external 
layer of hydrophilic CDs (Brewster, Loftsson, 2007).
In the internal layer, CH groups are bonded to the H3 
and H5 hydrogen atoms by glycosidic oxygen bridges. In-
tramolecular hydrogen bonds between the C2-OH groups 
of a glucose unit and the C3-OH groups of an adjacent 
glucose unit stabilize the CD structure, making it rigid 
(Loftsson, Brewster, 1997; Brewster, Loftsson, 2007).
Properties
The most important property of CDs is their ability to 
modify the physicochemical and biological characteristics 
of drugs. Their cavity can establish interactions through 
intermolecular forces with molecules, ions or radicals, act-
ing as a host substance. The resulting molecular complex 
is called an inclusion compound or a supramolecular com-
pound (Loftsson, Brewster, 1997; Li et al., 2010).
Table I details several characteristics of natural CDs. 
Table II lists the solubility of natural CDs in water and 
other organic solvents.
Of all natural CDs, β-CD has the lowest solubility, 
due to the high number of intramolecular hydrogen bonds 
among secondary hydroxyl groups within the molecule. 
These interactions make the structure rigid and prevent 
hydration by water molecules (Szejtli, 1994; Loftsson et 
al., 2005b).
FIGURE 2 - Timeline of relevant events in the history of cyclodextrins (CDs).
(treating the starch with Bacillus macerans), the final 
product was a mixture of a-CD (60%), b-CD (20%) and 
g-CD (20%), as well as small amounts of CDs with more 
than 8 units of glucose. However, purity was a major 
hurdle, becoming a critical issue that had to be overcome 
before the use of CDs could be made possible (Loftsson, 
Duchêne, 2007).
An alternative to address the issue of impurity was 
the use of biotechnological processes, which, along with 
other innovations, led to an increased purity of the result-
ing CD, thus making their use as pharmaceutical excipi-
ents feasible (Loftsson et al., 2005b).
Cyclodextrin structure
Due to the lack of free rotation about the glycosidic 
bonds and chain conformation of glucose units, CDs dis-
play a torus-like or hollow truncated cone shape. In this 
peculiar structure (Figure 3), the secondary hydroxyl 
FIGURE 3 - β-cyclodextrin (β-CD) structure, with representations 
of its size and position of hydroxyl groups.
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In α-CD, only 4 of 6 possible hydrogen bonds can 
be established, because one of the glucose units is in a 
distorted position. The γ-CD is a noncoplanar, more flex-
ible structure, thus being the most soluble of the three CDs 
(Loftsson et al., 2005b).
CDs are stable in alkaline medium, hydrolyze in 
strongly acidic medium and are resistant to enzymatic 
degradation by β-amylase, although CDs, particularly 
γ-CD, are susceptible to attack by α-amylase. CDs can 
form stable hydrates and their stability is identical to that 
of starch; thus, they can be stored for years without suf-
fering any degradation (Szejtli, 1994).
Toxicity
The safety profile of natural CDs and their deriva-
tives has been widely studied, and they have generally 
proven to be atoxic, because they only manage to cross 
biological membranes with some degree of difficulty. 
Thus, oral administration of CDs should not be regarded 
as a problem (Valle, 2004). 
Conversely, parenteral administration of γ-CD, 
2-hydroxypropyl-β-CD (2-HP-β-CD), sulfobutylether-β-
CD (SBE-β-CD), sulfate-β-CD and maltose-β-CD is safe 
to some degree. Studies have proven that several alkylating 
derivatives of α- and β-CDs are not recommended for use 
via this route of administration, because they show nephro-
toxicity and hemolytic activity (Loftsson, Duchêne, 2007).
CYCLODEXTRINS AND THEIR DERIVATIVES
It is possible to introduce chemical modifications 
into the primary and secondary hydroxyl groups of natural 
CDs through the bonds of several functional groups, thus 
TABLE I - Properties of natural cyclodextrins (CDs) (Adapted from: Szejtli, 1994; Veiga et al., 2006; Brewster, Loftsson, 2007; 
Wintgens and Amiel, 2010)
Property α-CD β-CD g-CD
Glucose units 6 7 8
Molecular weight (g/mol) 972 1135 1297
External diameter (Å) 14.6 15.4 17.5
Internal diameter (Å) 4.7-5.3 6.0-6.5 7.5-8.3
Height (Å) 7.9 7.9 7.9
Cavity volume (Å) 174 262 427
Shape of crystals Hexagonal lattice Monocyclic parallelograms Quadratic prism
pKa by potentiometry (25°C) 12.333 12.202 12.081
Diffusion constant at 40°C (m/s) 3.443 3.232 3.000
Hydrolysis by α-amylase Negligible Slow Fast
TABLE II - Solubility (g/100 mL) of natural cyclodextrins (CDs) (Adapted from: Szejtli, 1994; Loftsson et al., 2005b)
Solvent α-CD β-CD γ-CD
Water (25°C ) 14.5 1.85 23.2
Ethyl ether Insoluble Insoluble Insoluble
Chloroform Insoluble Insoluble Insoluble
Isopropanol Insoluble Insoluble > 0.1
Acetone Insoluble Insoluble > 0.1
Ethanol Insoluble Insoluble > 0.1
Methanol Insoluble Insoluble > 0.1
Glycerin Insoluble 4.3 ___
Propylene glycol 1 2 ___
Dimethyl sulfoxide 2 35 ___
Pyridine 7 37 ___
Ethylene glycol 9 21 ___
Dimethylformamide 54 32 ___
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TABLE III - Physicochemical properties of cyclodextrins (CDs) and their methylated derivatives. Source: Duchêne and Wouessidjewe, 
1990a and 1990b
CD Glucose unit
Molecular 
weight
Internal cavity 
diameter (Å)
Melting point 
(°C)
Aqueous 
solubility 25 °C 
(g/100 mL)
Water 
content
Surface tension 
(mN/m)
α –CD 6 973 5 275 15 10 71
Dimethyl-α-CD 6 1141 5 260-264 ---- ---- 65
Trimethyl-α-CD 6 1225 3-6 205 20 10 54
β-CD 7 1153 6 280 1.85 10 71
Dimethyl-β-CD 7 1331 6 295-300 57 1 62
Trimethyl-β-CD 7 1430 4-7 157 31 10 56
γ-CD 8 1297 8 275 23 10 71
Dimethyl-γ-CD 8 1521 8 255-260 ---- ---- 60
Trimethyl-γ-CD 8 1634 5-9 135 48 ---- 56
improving solubility, toxicity and increasing the inclusion 
capacity of original CDs and their derivatives (Uekama, 
Irie, 2004).
CD derivatives can be obtained by substitution with 
methyl, ethyl, carboxymethyl, hydroxyethyl, hydroxypro-
pyl, sulfobutyl, or saccharide groups or even by polymer-
ization of CDs. Many derivatives of natural CDs have been 
synthesized and characterized, but only a few are being 
used in studies involving new pharmaceutical excipients, 
including derivatives with methyl, hydroxypropyl and 
sulfobutyl ether substitutes (Mosher, Thompson, 2002; 
Uekama, Irie, 2004; Veiga et al., 2006).
HYDROPHILIC DERIVATIVES
Methylated derivatives
These derivatives can be obtained by selective 
methylation of all secondary hydroxyl groups in C2 and 
all primary hydroxyls in C6, methylation of all hydroxyl 
groups, including those in C3, or even randomly, in the C2, 
C3 or C6 positions (Imai et al., 1984; Veiga et al., 2006).
The methylated derivatives show alterations in their 
physical and chemical properties, as well as structural 
alterations when compared to natural CDs (Table III). 
Solubility in water and organic solvents is significantly 
greater; however, water solubility decreases as the tem-
perature increases (a reaction similar to that of nonionic 
surfactants). These derivatives exhibit reasonable stability 
in alkaline medium and are hydrolyzed by strong acids, 
giving rise to linear oligosaccharides (Uekama, Irie, 2004; 
Veiga et al., 2006).
Dimethyl-β-CD is the least vulnerable to acid hydro-
lysis. At the opposite extreme, trimethyl-γ-CD is the most 
susceptible, due to severe distortion in the configuration 
of the CD ring (Uekama, Irie, 2004).
Hydroxyalkyl derivatives
Hydroxyalkyl derivatives are one of the derivative 
groups most commonly used in drug complexation, being 
represented primarily by 2-hydroxyethyl-β-CD (2-HE-β-
CD), 2-HP-β-CD, 3-hydroxypropyl-β-CD (3-HP-β-CD), 
and 2.3-dihydroxypropyl-β-CD (2.3-DHP-β-CD). Obtain-
ing hydroxylated CDs from α-CD and γ-CD shows no sig-
nificant benefits compared to β-CD derivatives (Uekama, 
Otagari, 1998).
Obtaining hydroxyalkyl derivatives is a non-selec-
tive process that occurs by the condensation of hydroxy-
alkylating agents (hydroxypropyl and hydroxyethyl) in 
alkaline medium. The product of the condensation reaction 
is invariably a mixture of the respective derivatives, with 
various degrees of substitution. These mixtures not only 
prevent recrystallization, but also result in the conversion 
of the drug from a crystalline state into an amorphous state 
(Uekama, Otagari, 1998; Uekama et al., 2006).
The degree of substitution (S) expresses the number 
of hydroxyl groups replaced in a unit of glucose, which 
may range from 1 to 3, and the average degree of substi-
tution (DS) expresses the average number of hydroxyls 
replaced per unit of glucose, which is between 0 and 3. 
The average molar substitution (MS) expresses the num-
ber of hydroxypropyl groups per unit of glucose (Veiga 
et al., 2006).
Hydroxyalkyl derivatives have high water solubility 
and low hygroscopicity compared to the original CD; thus, 
in the presence of high humidity (> 90%), they dissolve 
in water adsorption. They have a surface tension identical 
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to that of natural CDs, but this characteristic is altered in 
derivatives with high degrees of substitution (Uekama, 
Otagari, 1998; Uekama et al., 2006).
Ramified derivatives
This class of CDs is obtained by chemical or en-
zymatic synthesis, where the substitution of primary or 
secondary hydroxyl groups for mono- or disaccharides 
through α-(1.6) bonds results in the formation of ramified 
CDs with high water solubility and chemical purity (Veiga 
et al., 2006).
Although ramified CDs have physical and chemical 
properties similar to those of natural CDs, such as surface 
tension and complexation capacity (Table IV), their solu-
bility in water, as well as in aqueous solutions of ethanol, 
methanol, acetone, formaldehyde and ethylene glycol, is 
superior (Duchêne Wouessidjewe, 1990b).
HYDROPHOBIC DERIVATIVES
CDs and their derivatives are mainly used in the 
pharmaceutical industry to improve the solubility and 
dissolution speed of poorly soluble drugs by means of in-
clusion complexation. However, some CD derivatives act 
in an opposite manner, with the main function of control-
ling the dissolution speed of water-soluble drugs. These 
derivatives are represented by ethylated and acylated CDs 
(Uekama et al., 2006).
Ethylated derivatives
The aqueous solubility of CDs is reduced when their 
hydroxyl groups are replaced with alkyl groups larger 
than methyl, through an ether or ester bond. Solubility 
decreases proportionally to the rate of substitution, which 
increases in less polar solvents, thus presenting fewer 
hygroscopic characteristics and lower surface tension 
(Uekama et al., 2006; Mosher, Thompson, 2002).
Acylated derivatives
These are obtained by substitution of all β-CD 
hydroxyl groups for different alkyl chains, resulting in 
reduced aqueous solubility, melting point and rate of al-
kaline hydrolysis as the respective alkyl chain increases. 
In concentrated solutions of β-CD derivatives in organic 
solvents (ethanol, acetone or chloroform), the viscosity 
increases due to a gelation process occurring after the 
solvent has evaporated (Mosher, Thompson, 2002).
Differently from the ethylated β-CD derivatives, 
acylates are easily eliminated from the organism after al-
kaline hydrolysis, yielding the original CD (β-CD). This is 
an important factor in the event of enteral administration, 
because this CD is not toxic when administered by this 
route (Mosher, Thompson, 2002).
Ionizable derivatives
The substitution of CD hydroxyl groups for ioniz-
able groups imparts hydrophilic characteristics to the 
new structure, as well as pH-dependent complexation 
capacity. In other words, solubility is low in acidic me-
dium, becoming greater in neutral or alkaline media. This 
pH-dependent characteristic is a result of the ionization 
of the carboxylic groups that show a pKa value around 
3.5 (Ma et al., 2000).
Among all ionizable CDs, one in particular stands 
out: SBE-β-CD. This is a polyanionic CD formed when 
the 2, 3 and 6 hydroxyl groups of β-CD glucose units are 
substituted for sulfobutyl ether groups, which are totally 
ionized over a broad pH range. They provide a negatively 
TABLE IV - Physicochemical properties of cyclodextrins (CDs) and their ramified derivatives (Duchêne, Wouessidjewe, 1990a 
and 1990b)
Molecule Glucose units Molecular weight Aqueous solubility 25 °C 
(g/100 mL)
Surface tension 
(mN/m)
α-CD 6 973 18.0 71
Glycosyl-α-CD 7 1135 89.0 ----
β-CD 6 1135 18.5 71
Glycosyl-β-CD 8 1297 97.0 71
Diglycosyl-β-CD 9 1459 140 ----
Maltosyl-β-CD 9 1459 50 70
Dimaltosyl-β-CD 11 1789 50 71
γ-CD 8 1297 23 71
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TABLE V - Details of some characteristics of cyclodextrin (CD) derivatives
Derivative Method Characteristics Advantages Disadvantages
Hydrophilic derivatives
Methylates Methylation Water solubility 
decreases as temperature 
increases
Solubility in water 
greater than natural CD;
very soluble in organic 
solvents 
Hydrolyzed in the 
presence of strong acids
Hydroxyalkyl Condensation of 
hydroxyalkylating 
agents in alkaline 
medium
Surface tension identical 
to that of natural CD. 
Lower surface tension 
observed only in 
derivatives with high rate 
of substitution
Highly soluble in water;
low hygroscopicity
In the presence of 
humidity > 90%, they 
dissolve in water 
adsorption 
Ramified Chemical or enzymatic  
synthesis 
Substitution of 
primary and secondary 
hydroxyls for mono- and 
disaccharides through 
α-(1.6) bonds.
They present three 
types of hydrolyzable 
glycosidic bonds: α-(1.6) 
between the CD ring and 
the ramification unit, 
α-(1.4) of the glucose 
units of lateral chain, 
and α-(1.4) bonds of the 
chain ring
High solubility in water 
and aqueous solutions 
of methanol, ethanol, 
acetone, formaldehyde 
and ethylene glycol 
Chemical degradation 
increases as pH 
decreases
Hydrophobic derivatives
Ethylates Partial ethylation of 
hydroxyl groups
Solubility decreases 
proportionally to the 
rate of substitution and 
increases in less polar 
solvents
Prolonged drug release 
time
Reduction in aqueous 
solubility of CDs
Acylates Substitution of 
hydroxyl groups for 
different alkyl chains
Aqueous solubility, 
melting point and rate 
of alkaline hydrolysis 
decreases as alkyl chain 
increases
Easily eliminated from 
the organism after 
alkaline hydrolysis
High viscosity in 
solvents such as 
ethanol, acetone, and 
chloroform. Gelation 
occurs after the solvent 
evaporates
Ionizable Substitution of 
hydroxyl groups for 
ionizable groups
Hydrophily and capacity 
for pH-dependent 
complexation
High solubility in 
neutral or alkaline pH
Low solubility in acidic 
pH
charged polar head, attached to a hydrophobic tail, which 
is connected to the internal cavity (Stella et al., 2002). 
SBE-β-CD has a peculiar structure, where substi-
tute groups that exercise mutual electrostatic repulsion 
are in a favorable position for entry into the CD cavity. 
As a result, there is an increase in its hydrophobic proper-
ties and complexation capacity, which is the reason for 
its wide-ranging pharmaceutical application. Another 
relevant attribute is the fact that the charge of the CD 
molecule is located at a site as far as possible from the 
hydrophobic cavity, thus intensifying its solubilizing 
capacity (Zia et al., 2001).
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FORMATION OF INCLUSION COMPLEXES
The truncated cone structure of CDs, which are 
open at both ends, enables the inclusion of a wide vari-
ety of organic molecules (apolar drugs) in their central 
cavities. Host-guest complexes, or drug-CD complexes 
also known as inclusion complexes or compounds, result 
from the association between host molecules (CDs) and 
encapsulated molecules (drugs) (Szejtli, 1998; Tsai et 
al., 2010).
The formation of a complex (Figure 4) in an aque-
ous solution takes place when water molecules are re-
moved from the apolar cavity of CDs (which are in an 
energetically unfavorable environment due to the nature 
of the polar-polar interaction) and substituted for a guest 
molecule or lipophilic group with polarity, size and shape 
compatible with that of the CD structure (Szejtli, 1998; 
Rafati et al., 2009).
This process is energetically favorable and contrib-
utes to an increase in complex stability, because it causes 
changes in enthalpy and a reduction in the total energy of 
the system (Saenger, 1980; Veiga et al., 2006).
Furthermore, other forces are involved in the for-
mation and stabilization of inclusion complexes, such as 
van der Waals interactions (dipole-dipole interaction and 
London dispersion forces), 3-center, 2-electron bonds 
(between guest molecule and CD hydroxyl groups), 
hydrophobic interactions, release of deformation energy 
from the macromolecular ring of CDs, and steric effects 
(Saenger, 1980; Bekers et al., 1991; Szejtli, 1998; Bibby 
et al., 2000; Flasinski et al., 2010).
The complexes formed are usually more water 
soluble than the active ingredients they contain as well as 
more stable in solution form. They also dissociate easily 
in order to release the drug molecule (Lofttson et al., 2005 
a, b; Wintgens, Amiel, 2010).
Obtaining complexes with CDs may occur in the 
liquid, semi-solid or solid phases. In the liquid phase, the 
following methods have been suggested: coprecipitation, 
coevaporation, neutralization, freeze-drying, and drying 
by pulverization. In the solid phase, the most common 
methods are grinding or supercritical fluid technology, 
while malaxation is employed in the semi-solid phase 
(Valle, 2004).
Drug-CD complexes have an extremely rapid and 
dynamic formation and dissociation kinetics in solution 
form, continually forming and dissociating by covalent 
bonds. Complex dissociation is expressed quantitatively 
by the dissociation constant (Kc), where [drug-CD], [drug] 
and [CD] are the concentrations of the complexed drug, the 
free drug and the free CD, respectively. This dissociation 
constant ranges from 0 to 105, where 0 indicates that the 
drug is incapable of forming a complex with CD and 105 
indicates the upper limit of drug-CD complexes (Tompson, 
1997; Stella, Rajewski, 1997; Veiga et al., 2006; Loftsson 
et al., 2007; Rafati et al., 2009).
  (1)
The dissociation kinetics will be inversely propor-
tional to the strength of the bond between the CD and the 
drug, i.e., the slower the dissociation kinetics, the stronger 
the drug-CD bond (Kc). Even in this situation, the dis-
sociation velocity of the complexes is considered to be 
practically instantaneous (Loftsson et al., 2007).
There are several techniques for characterizing 
inclusion complexes, with X-ray diffraction, Fourier 
transform infrared (FTIR) spectroscopy, thermal analysis, 
Raman spectroscopy, solubility and scanning electron 
microscopy (SEM) being the most significant ones (Veiga 
et al., 2006; Heise et al., 2010; Tsai et al., 2010; Jug et 
al., 2011).
Molecular modeling studies have gained strong 
emphasis in the investigation of complexation with CDs. 
This allows the construction of three-dimensional models 
of drug-CD complexes, visualization of structural integ-
rity, and intra- and intermolecular interactions (Seridi, 
Boufelfel, 2011; Leila et al., 2011; Eid et al., 2011; Ge et 
al., 2011; Mishur et al., 2011).
CYCLODEXTRINS IN THE PHARMACEUTICAL 
INDUSTRY
CDs and their derivatives are present in several ar-
eas, most notably in the pharmaceutical industry, where 
they are extensively used because of their complexing 
FIGURE 4 - Graphical representation of the formation of 
inclusion complexes. A: drug molecule; B: cyclodextrin (CD) 
molecule; C: CD cavity; D: water molecules; E: drug-CD 
complex. Adapted from: Szejtli, 1998; Veiga et al., 2006.
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TABLE VI - Pharmaceutical products containing cyclodextrins (CDs) (Loftsson et al., 2004; Szejtli 2004; Loftsson et al., 2005 a, b; 
Loftsson, Duchêne, 2007)
DRUG / CD TRADE NAME DOSAGE FORM COUNTRY
α-CD
   Alprostadil (PGE1) Provastatin®, Rigidur® Solution, intravenous 
solution
Japan, Europe, USA
   OP – 1206 Opalmon® Tablet Japan
   Cefotiam hexetil hydrochloride Pansporin T® Tablet Japan
β-CD
Benexate hydrochloride Ulgut®, Lonmiel® Capsule Japan
Cephalosporin (ME 1207) Meiact® Tablet Japan
Chlordiazepoxide Transillium® Tablet Argentina
Dexamethasone Glymesason® Cream Japan
Diphenhydramine hydrochloride, Chlorotheophylline Stada-Travel® Sublingual tablet Europe
Iodine Mena-Gargle® Solution Japan
Nicotine Nicorette®, Nicogum® Sublingual tablet, 
chewing gum
Europe
Nimesulide Nimedex® Tablet Europe
Nitroglycerin Nitropen® Sublingual tablet Japan
Omeprazole Omebeta® Tablet Europe
PGE2 Prostarmon E® Sublingual tablet Japan
Piroxicam Brexin®, Flofene®, 
Cicladol®
Tablet, suppository, 
solution
Europe and Brazil
Tiaprofenic acid Surgamyl® Tablet Europe
2-hydroxypropyl-β-CD
Cisapride Prepulsid® Suppository Europe
Itraconazole Sporanox® Oral solution and 
intramuscular injection
Europe, USA
Mitomycin Mitozytrex® Intravenous infusion Europe, USA
Methyl-β-CD
Chloramphenicol Clorocil® Ophthalmic solution Europe
17β-estradiol Aerodiol® Nasal spray Europe
Sulfobutylether-β-CD
Voriconazole Vfend® Intravenous solution Europe, USA
Ziprasidone mesylate Geodon®, Zeldox® Intravenous solution Europe, USA
2-hydroxypropyl-γ-CD
Diclofenac sodium Voltaren® Ophthalmic solution Europe
Tc-99m teoboroxime Cardiotec® Intravenous solution USA
properties that are capable of modifying the physico-
chemical characteristics of poorly water-soluble drugs, 
thus changing the dissolution profile of their solid dosage 
forms (Loftsson, Duchêne, 2007).
The first pharmaceutical product using CDs in its 
formulation was E2/β-CD prostaglandin, in the form 
of a sublingual tablet, which was launched in Japan in 
1976. The use of CDs for the purpose of modifying drug 
properties is a reality in the pharmaceutical industry, and 
currently, it is possible to name about 40 products formu-
lated with CDs on the global market, especially in Europe, 
Japan, and USA. Table VI details several CD-containing 
pharmaceutical products (Loftsson et al., 2005 b; Lofts-
son, Duchêne, 2007).
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FORMATION OF TERNARY COMPLEXES
When a water-soluble polymer, a CD and a drug are 
mixed together in a solution to obtain the so-called ternary 
complexes, it is possible to increase drug solubilization, 
when compared to the polymer and CD separately, which 
is a result of the synergistic effect between these compo-
nents (Loftsson et al., 1994). An example is the synergistic 
effect resulting from the addition of hydroxypropyl meth-
ylcellulose (HPMC) to the complex formed by SBE-β-CD 
and carbamazepine, with a consequent increase in drug 
solubility in the resulting ternary complex (Smith et al., 
2005).
Formulations containing drug:CD complexes with 
the addition of a water-soluble polymer have proven to be 
capable of increasing the bioavailability of formulations 
while reducing the amount of CD by up to 80% (Loftsson, 
Fridriksdóttir, 1998; Mura et al., 2001). In the presence 
of water, the polymer aids in the wettability of particles, 
resulting in accelerated dissolution and increased amount 
of drug delivered in vitro (Lahiani-skiba et al., 2006).
The interaction of water-soluble polymers with drug 
molecules may occur by means of ion-ion, ion-dipole and 
dipole-dipole electrostatic bonds, van der Waals force, or 
3-center, 2-electron bonds (Ribeiro et al., 2003). Similarly, 
the interaction between polymers and CDs and drug:CD 
complexes begins to occur on the external surface of the 
CD molecule. CDs, polymers and drug:CD complexes 
form aggregates capable of solubilizing drugs and other 
hydrophobic molecules (Loftsson et al., 2007), as shown 
in Figure 5. 
Several types of interactions between polymers and 
drugs may be established as a result of the structural dif-
ference and polarity of CD molecules, which may give rise 
to various complexation efficiencies. Povidone (PVP) and 
HPMC polymers were evaluated in the complexation of 
vinpocetine with β-CD and SBE-β-CD. The best complex-
ation efficiency results were obtained for PVP with β-CD 
and for HPMC with SBE-β-CD (Ribeiro et al., 2003).
The resulting chemical structure of the drug is still 
unknown, as is the nature of the interaction between CDs 
and the water-soluble polymer, but it is recognized that, in 
aqueous solutions, polymers stabilize micelles and other 
types of aggregates, reduce CD mobility and increase the 
solubility of complexes by changing the hydration proper-
ties of CD molecules (Loftsson et al., 2005b).
This process can be accelerated by heating the 
ternary system. Thus, it is possible to activate the bonds 
between system components during the preparation of 
complexes by heating them in an autoclave (120 to 140 ºC) 
for 20 to 40 minutes, in an ultrasound bath (over 30 ºC) for 
1 hour, or even with microwaves at 40 ºC for 5 minutes 
(Loftsson et al., 2005b).
Thermodynamic parameters (entropy and enthalpy) 
prove that different forces and/or mechanisms are at play 
in the formation of the complex, depending on the pres-
ence or absence of a polymer. Addition of polymers chang-
es the entropy (ΔSº) of the system, which becomes more 
negative, indicating the formation of a more organized 
structure with greater enthalpy (Loftsson et al., 1994).
Studies have proven that HPMC and PVP increase 
the complexation of hydrocortisone, dexamethasone and 
naproxen with β-CD (Ammar et al., 2006). Valero and col-
leagues (2003) observed that, at low PVP concentrations, 
the complexation process occurs entropically, and in larger 
proportions, it occurs enthalpically.
COMPLEXATION EFFICIENCY AND THE STA-
BILITY CONSTANT
The stability constant (KC), calculated from the 
phase solubility diagram (drug concentration x CD 
concentration), can be considered an apparent stability 
constant for several complexes, describing the combined 
effect of various structures on the solubility of a drug. Ac-
cordingly, a definition for complexation efficiency (CE) 
as a more precise method for evaluating the solubilizing 
effect of CDs has been proposed (Loftsson et al., 2007).
The stability constant of a complex is determined 
from the slope of the phase diagram and the intrinsic 
solubility of a drug (S0) (Equation 1). Theoretically, the 
intersection (Sint) of the phase solubility diagram should be 
identical to S0. However, drugs with an aqueous solubil-
ity of less than 0.1 mM show an intersection in the phase 
solubility diagram that is generally much greater than S0, 
FIGURE 5 - Representation of ternary complex formation 
between drugs, cyclodextrins (CDs) and water-soluble 
polymers. Source: Veiga et al., 2006.
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TABLE VII - Polymers most commonly used to obtain ternary 
complexes
Nature of 
polymers Polymer
Natural Pectin
Mucin
Agar 
Alginic acid
Carrageenin
Casein
Schizophyllan
Gelatin
Semi-synthetic Methyl cellulose (MC)
Hydroxyethyl cellulose (HEC)
Hydroxypropyl cellulose (HPC)
Hydroxyethyl  methyl cellulose (HEMC)
Carboxymethyl cellulose (CMC)
Synthetic Povidone (PVP)
Polyethylene glycol (PEG)
Copovidone
Polyvinyl alcohol (PVA)
thus resulting in imprecise KC values. Therefore, CE is 
calculated from the slope of phase solubility diagrams and 
is independent of S0 and Sint, in accordance with Equation 
2 (Loftsson et al., 2007). In Equation 3, K1:1 represents the 
stability constant 1:1 ratio between drug and CD, and D 
represents drug concentration.
  (2)
  (3)
Some researchers consider that complexes with KC 
values ranging between 200 and 5000 M-1 are applicable 
to dosage formulations, while KC values between 7 and 
100 M-1 were deemed sufficient by others, because they 
were able to improve the physical and chemical proper-
ties of drugs compared to non-complexed forms (Veiga 
et al., 2006).
KC values are widely used to determine the stoichi-
ometry of complexes, as well as to compare the affinity 
of drugs for CDs, thus determining whether the addition 
of water-soluble polymers to the system actually results 
in greater interaction between the components (Loftsson 
et al., 2007).
POLYMERS USED TO OBTAIN TERNARY 
COMPLEXES
Obtaining complexes with CDs, drugs and water-
soluble polymers has gained greater acceptance due to 
the relatively low cost of polymers (Lahiani-Skiba et 
al., 2006). The most important requirements in choosing 
polymers to form inclusion complexes with drugs and CDs 
are water solubility and absence of biological activity. The 
most commonly used polymers for this purpose may be 
classified as natural, semi-synthetic and synthetic (Veiga 
et al., 2006), as detailed in Table VII.
There is no pre-established range of ideal polymer 
concentration for obtaining ternary complexes. However, 
it is known that, at high concentrations, the viscosity of 
the medium increases, thus impairing complexation. The 
amount of polymer must be such that the solubilizing ef-
fect is maximized, but not sufficient to cause a significant 
increase in viscosity (Ribeiro et al., 2003).
In studies by Loftsson and colleagues (1994) with 
hydrocortisone, 17β-estradiol and triamcinolone in an HP-
β-CD 10% (p/v) aqueous solution, the ideal concentration 
of polymers ranged from 0.05 to 0.25% (p/v) and greater 
concentrations led to a reduction in drug solubility. Table 
VIII details the complexation solubility and efficiency of 
some drugs in their free form and in ternary complexes.
PHARMACEUTICAL APPLICATIONS OF TER-
NARY INCLUSION COMPLEXES
Most drugs with low aqueous solubility have organic 
solvents, emulsifiers and extreme pH conditions in their 
formulations, which can cause irritation and other adverse 
reactions (Del Valle, 2004). The drug:CD:polymer com-
plexes can be administered in any dosage form for the 
treatment of a variety of ailments, depending on the bio-
logical activity of the complexed drug. Research on ternary 
complexes has gained prominence in recent decades, and it 
is therefore possible to find a considerable number of stud-
ies in which drug:CD:water-soluble polymers obtained for 
several drugs are described (Table IX).
CONCLUSION
Improving the solubility of poorly soluble drugs is 
one of the main applications of CDs and their derivatives, 
which have the ability to encapsulate organic molecules 
in their cavities, thus forming inclusion complexes, which 
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TABLE IX - Ternary complexes between drugs, cyclodextrins (CDs) and water-soluble polymers, as described in the scientific 
literature
Drug CD Water-soluble polymer Reference
17β-estradiol HP-β-CD CMC Loftsson et al., 1994
HP-β-CD PVP Loftsson, Brewster, 1996
Acetazolamide β-CD HPMC, CMC, PVP Loftsson, Fridrilksdóttir, 1998
HP-β-CD CMC, PVP Loftsson et al., 1994
HP-β-CD HPMC, CMC, PVP Loftsson et al., 2005b
Triamcinolone 
acetonide
HP-β-CD CMC Loftsson et al., 1994
Alprazolam β-CD HPMC, CMC, PVP Loftsson , Fridrilksdóttir, 1998
HP-β-CD CMC Loftsson et al., 1994
Carbamazepine SBE-β-CD HPMC, PVP Smith et al., 2005
HP-β-CD CMC, PVP Loftsson et al., 1994
β-CD HPMC, CMC, PVP Loftsson, Fridrilksdóttir, 1998
HP-β-CD HPMC, CMC, PVP Brewster, Loftsson, 2007
Celecoxib HP-β-CD HPMC, PEG, PVP Chowdary, Srinivas, 2006
Clotrimazol HP-β-CD CMC, PVP Loftsson et al., 1994
Dexamethasone HP-β-CD HPMC Loftsson et al., 1994
β-CD HPMC, CMC, PVP Loftsson, Fridrilksdóttir, 1998
Diazepam HP-β-CD CMC Loftsson et al., 1994
Econazole HP-β-CD CMC, PVP Loftsson et al., 1994
Ethoxzolamide HP-β-CD CMC, PVP Loftsson et al., 1994
β-CD HPMC, CMC, PVP Loftsson, Fridrilksdóttir, 1998
TABLE VIII - Solubility values for some drugs in their free form (S0) and in ternary complexes (STERNARY), and their respective 
complexation efficiency (CE) values (Adapted from Brewster and Loftsson, 2007)
Drug Cyclodextrin 
(CD)
Polymer Polymer 
concentration
S0 
(mg/mL)
STERNARY 
(mg/mL)
CE
Acetazolamide HP-β-CD Absent - 0.64 3.60 0.197
HP-β-CD HPMC 0.10% 0.90 4.40 0.356
HP-β-CD CMC 0.25% 0.59 3.60 0.209
HP-β-CD PVP 0.25% 0.94 3.70 0.273
Carbamazepine HP-β-CD Absent - 0.26 0.65 0.548
HP-β-CD HPMC 0.10% 0.33 8.00 0.829
HP-β-CD CMC 0.25% 0.18 8.40 0.709
HP-β-CD PVP 0.25% 0.28 8.50 0.701
Finasteride RM-β-CD Absent - 0.06 12.30 0.708
RM-β-CD HPMC 0.10% 0.06 11.60 0.789
RM-β-CD CMC 0.25% 0.06 11.50 0.805
RM-β-CD PVP 0.25% 0.06 11.60 0.844
Oxazepam HP-β-CD Absent - 0.05 2.10 0.109
HP-β-CD HPMC 0.10% 0.27 2.10 0.076
HP-β-CD CMC 0.25% 0.05 1.50 0.127
HP-β-CD PVP 0.25% 0.10 1.40 0.115
CMC = carboxymethyl cellulose; HP-β-CD = hydroxypropyl-β-CD; HPMC = hydroxypropyl methylcellulose; PVP = povidone; 
RM-β-CD = randomly methylated-β-CD.  
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Drug CD Water-soluble polymer Reference
Finasteride RM-β-CD HPMC, CMC, PVP Brewster, Loftsson, 2007
HP-β-CD PVP Asbahr et al., 2009 
Gemfibrozil β-CD PVP Sami, Philip, Pathak, 2010
Gefitinib HP-β-CD PVP, HPMC Phillip Lee et al., 2009
Glibenclamide β-CD, HP-β-CD, SBE-β-CD HPMC Savolainen et al., 1998 
Glimepiride β-CD, HP-β-CD, SBE-β-CD HPMC, PEG, PVP Ammar et al., 2006
Griseofulvin a-CD, b-CD and g-CD PEG Wulff, Aldén, 1999
b-CD CMC Dhanaraju et al., 1998
Hydrocortisone HP-β-CD CMC Loftsson et al., 1994
HP-β-CD HPMC, PVP Loftsson, Sigurdardottir, 1994
HP-β-CD HPMC, CMC, PVP Loftsson et al., 2005b
RM-β-CD HPMC, CMC, PVP Loftsson et al., 2005b
Indomethacin a-CD, b-CD and g-CD PEG Wulff, Aldén, 1999
Irbesartan b-CD PEG, PVP Hirlekar, Sonawane, Kadam, 2009
Lamivudine b-CD PVA Selvam, Geetha, 2008
Lamotrigine b-CD PEG, PVP Shinde et al., 2008
Lovastatin b-CD, RM-β-CD PVP Süle, Csempesz, 2008
Meloxicam HP-β-CD PVP El-Maradny et al., 2008
Methazolamide β-CD HPMC, CMC, PVP Loftsson, Fridrilksdóttir, 1998
HP-β-CD HPMC, CMC, PVP Loftsson et al., 2005b
Miconazol HP-β-CD CMC Loftsson et al., 1994
Midazolam SBE-β-CD HPMC Loftsson et al., 2001
Naproxen β-CD, HP-β-CD PVP Mura et al., 2001
Nicardipine β-CD PEG Quaglia et al., 2001
Oxazepam HP-β-CD CMC, PVP Loftsson et al., 1994
HP-β-CD HPMC, CMC, PVP Brewster, Loftsson, 2007
Prednisolone HP-β-CD CMC Loftsson et al., 1994
β-CD HPC Uekama et al., 1983
Progesterone HP-β-CD PEG Nandi et al., 2003
β-CD PEG Lahiani-Skiba et al., 2006
HP-β-CD CMC, PVP Loftsson et al., 1994
Simvastatin b-CD, RM-β-CD PVP Süle, Csempesz, 2008
Sulfamethoxazole HP-β-CD CMC, PVP Loftsson et al., 1994
β-CD HPMC, CMC, PVP Loftsson, Fridrilksdóttir, 1998
HP-β-CD HPMC, CMC, PVP Loftsson et al., 2005b
Temazepam HP-β-CD CMC Loftsson et al., 1994
Terfenadine β-CD CMC Choi et al., 2001
Triclosan β-CD CMC Loftsson, 1999
Trimethoprim HP-β-CD PVP Loftsson et al., 1994
Tropicamide HP-β-CD HPMC, CMC, PVP Cappello et al., 2001
Vinpocetine β-CD, SBE-β-CD HPMC, PVP Ribeiro et al., 2003
CMC = carboxymethyl cellulose; HP-β-CD = hydroxypropyl-β-CD; HPMC = hydroxypropyl methylcellulose; PEG = 
polyethylene glycol; PVP = povidone; RM-β-CD = randomly methylated-β-CD; SBE-β-CD = sulfobutylether-β-CD.
TABLE IX - Ternary complexes between drugs, cyclodextrins (CDs) and water-soluble polymers, as described in the scientific 
literature (cont.)
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in turn modify the physicochemical characteristics of such 
drugs. The drug:CD:water-soluble polymer complex rep-
resents an attractive alternative, especially in cases where 
a high amount of CD is required for complexation, which 
significantly increases the volume of dosage forms. Thus, 
it is possible to obtain solid-form medications with an op-
timized dissolution profile, which may result in improved 
bioavailability.
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